Clinical responses and complications
| Patient | F/U (months) | Exacerbationspost-BMT* | Δ EDSS† | Δ AI‡ | Δ SNRS§ | Δ 9-HPT(%) | Oligoclonalbands b/a | Complications |
|---|---|---|---|---|---|---|---|---|
| AI, ambulation index; b/a, before/after BMT; EBV-PTLD, Epstein-Barr virus related post-transplantation lymphoproliferative disorder; F/U, follow up; 9-HPT, nine hole peg test; NA, not allowed; SNRS, Scripps neurological rating scale. | ||||||||
| *Total number of exacerbations during follow up; †EDSS: 0–10, positive Δ scores indicate worsening, comparing baseline with last observation during follow up, sustained for 6 months; ‡SNRS: 0–100, positive Δ scores indicate improvement; §AI: 0–9, positive Δ scores indicate worsening; ¶9-HPT: % reduction in seconds, positive Δ scores indicate worsening. | ||||||||
| 1 | 36 | 1 | 2 | 5 | −23 | 64 | −/− | Antithyroid antibodies |
| 2 | 36 | 1 | 1.5 | 4 | −13 | 78 | NA | |
| 3 | 36 | 1 | 1.5 | 3 | −15 | 71 | +/+ | Died 5 years after BMT |
| 4 | 36 | 0 | 0 | 2 | 4 | 23 | −/NA | Autoimmune thyroiditis |
| 5 | 36 | 4 | 1.5 | 3 | −21 | 13 | NA | |
| 6 | 36 | 0 | −1.0 | −1 | 10 | −36 | −/− | |
| 7 | 36 | 0 | −0.5 | 0 | 1 | −53 | NA | Myelodysplastic syndrome |
| 8 | 36 | 0 | 1 | 3 | −18 | 34 | NA | |
| 9 | 30 | 0 | 0 | −1 | −7 | 3 | +/− | CSF leakage |
| 10 | 24 | 1 | 2 | 4 | −15 | 187 | +/+ | |
| 11 | 24 | 0 | 1.5 | 3 | −2 | 47 | +/+ | |
| 12 | 24 | 0 | 0.5 | 2 | −10 | 67 | −/NA | |
| 13 | 12 | 0 | 0 | 0 | 6 | −2 | +/+ | EBV-PTLD |
| 14 | 7 | 0 | 0.5 | 1 | −11 | 114 | +/+ | Autoimmune thyroiditis |